Inhibition of monoamine oxidase-B by condensed pyridazines and pyrimidines: Effects of lipophilicity and structure-activity relationships

Journal of Medicinal Chemistry

Volumn 41, Issue 20, 1998, Pages 3812-3820

  Altomare, Cosimo ^a   Cellamare, Saverio ^a   Summo, Luciana ^a   Catto, Marco ^a   Carotti, Angelo ^a   Thull, Ulrike ^b   Carrupt, Pierre Alain ^b   Testa, Bernard ^b   Stoeckli Evans, Helen ^c  

^a UNIVERSITY OF BARI   (Italy)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

^c UNIVERSITY OF NEUCHÂTEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; PYRIDAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ARTICLE; ENZYME ACTIVITY; ENZYME CONFORMATION; ENZYME INHIBITION; LIPOPHILICITY; PARTITION COEFFICIENT; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; X RAY CRYSTALLOGRAPHY;

ANIMALS; BRAIN; CRYSTALLOGRAPHY, X-RAY; LINEAR MODELS; MITOCHONDRIA; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MONOAMINE OXIDASE INHIBITORS; PYRIDAZINES; PYRIMIDINES; RATS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0032563927     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm981005y     Document Type: Article

References (57)

1. Tipton, K. F. Enzymology of monoamine oxidase. Cell Biochem. Funct. 1986, 4, 79-87.
2. Kalgutkar, A. S.; Castagnoli, N., Jr.; Testa, B. Selective inhibitors of monoamine oxidase (MAO-A and MAO-B) as probes of its catalytic site and mechanism. Med. Res. Rev. 1995, 15, 325-388.
3. (a) Bach, A. W. J.; Lan, N. C.; Johnson, D. L.; Abell, C. W.; Bembenek, M. E.; Kwan, S. W.; Seeburg, P. H.; Shih, J. C. cDNA cloning of human liver monoamine oxidase A and B: Molecular basis of differences in enzymatic properties. Proc. Natl. Acad. Sci. U.S.A. 1988, 85, 4934-4938.
4. (b) Grimsby, J.; Chen, K.; Wang, L. J.; Lan, N. C.; Shih, J. C. Molecular basis of human MAO A and B. Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 3637-3641.
5. (a) Wu, H.-F.; Chen, K.; Shih, J. C. Site-directed mutagenesis of monoamine oxidase A and B: role of cysteines. Mol. Pharmacol. 1993, 43, 888-893.
6. (b) Zhong, B.; Silverman, R. B. Identification of the active site cysteine in bovine liver monoamine oxidase B. J. Am. Chem. Soc. 1997, 119, 6690-6691.
7. (c) Tsugeno, Y.; Ito, A.; A key amino acid responsible for substrate selectivity of monoamine oxidase A and B. J. Biol. Chem. 1997, 272, 14033-14036.
8. Langston, J. W.; Ballard, P.; Tetrud, J. W.; Irwin, I. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983, 219, 979-980.
9. Strolin-Benedetti, M.; Dostert, P. L. Monoamine oxidase: From physiology and pathophysiology to the design and clinical application of reversible inhibitors. In Advances in Drug Research; Testa, B., Ed.; Academic Press: London, U.K., 1992; Vol. 23, pp 65-125.
10. (a) Allain, H.; Bentué-Ferrer, D.; Belliard, S.; Derousné, C. Pharmacology of Alzheimer's disease. In Progress in Medicinal Chemistry; Ellis, C. P., Luscombe, D. K., Eds; Elsevier Science: Amsterdam, NL, 1997; Vol. 34, pp 1-67.
11. (b) Freedman, M.; Rewilak, D.; Xerri, T.; Cohen, S.; Gordon, A. S.; Shandling, M.; Logan, A. G. L-deprenyl in Alzheimer's disease: Cognitive and behavioral effects. Neurology 1998, 50, 660-668.
12. (c) Bongioanni, P.; Mondino, C.; Boccardi, B.; Borgna, M.; Castagna. M. Neurodegener. 1996, 5, 351-357.
13. (a) Youdim, M. B. H.; Finberg, J. P. M. New directions in monoamine oxidase A and B selective inhibitors and substrates. Biochem. Pharmacol. 1991, 41, 155-162.
14. (b) Cesura, A. M.; Pletscher, A. The new generation of monoamine oxidase inhibitors. In Progress in Drug Research; Jucker, E., Ed.; Birkhäuser Verlag: Basel, Switzerland, 1992; Vol. 38, pp 171-297.
15. (c) Da Prada, M.; Kettler, R.; Keller, H. H.; Cesura, A. M., Richards, J. G.; Saura Marti, J.; Muggli-Maniglio, D.; Wyss, P. C.; Kyburz, E.; Imhof, R. From moclobemide to Ro 19-6327 and Ro 41-1049: The development of a new class of reversible selective MAO-A and MAO-B inhibitors. J. Neural Transm. [Suppl.] 1990, 29, 279-292.
16. Altomare, C.; Carrupt, P.-A.; Gaillard, P.; El Tayar, N.; Testa, B.; Carotti, A. Quantitative structure-metabolism relationship analyses of MAO-mediated toxication of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and analogues. Chem. Res. Toxicol. 1992, 5, 366-375.
17. Thull, U.; Kneubühler, S.; Gaillard, P.; Carrupt, P.-A.; Testa, B.; Altomare, C.; Carotti, A.; Jenner, P.; McNaught, K. St. P. Inhibition of monoamine oxidase by isoquinoline derivatives: Qualitative and 3D-quantitative structure-activity relationships. Biochem. Pharmacol. 1995, 50, 869-877.
18. (a) Kneubühler, S.; Carta, V.; Altomare, C.; Carotti, A.; Testa B. Synthesis and monoamine oxidase inhibitory activity of 3-substituted 5H-indeno[1,2-c]pyridazines. Helv. Chim. Acta 1993, 76, 1954-1963.
19. (b) Kneubühler, S.; Thull, U.; Altomare, C.; Carta, V.; Gaillard, P.; Carrupt, P.-A.; Carotti, A.; Testa, B. Inhibition of monoamine oxidase-B by 5H-indeno[1,2-c]pyridazines: Biological activities, quantitative structure-activity relationships (QSARs) and 3D-QSARs. J. Med. Chem. 1995, 38, 3874-3883.
20. Gaillard, P.; Carrupt, P.-A.; Testa, B.; Boudon, A. Molecular lipophilicity potential, a tool in 3D QSAR: Method and applications. J. Comput.-Aided Mol. Des. 1994, 8, 83-96.
21. Heinish, G.; Jentzsch, A.; Pailer, M. C-4 Substituted pyridazines by homolitic alkylation and acylation. Monatsh. Chem. 1974, 105, 648-652.
22. Stetter, H.; Siehnhold, E. Zur kenntnis des kondensation-sproduktes aus dihydroresorcin und phenacylbromid. Chem. Ber. 1955, 88, 271-274.
23. (a) Carotti, A.; Carta, V.; Campagna, F.; Altomare, C.; Casini, G.; An efficient route to biologically active 5H-indeno[1,2-c]-pyridazin-5-ones. Farmaco 1993, 48, 137-141.
24. (b) Altomare, C.; Campagna, F.; Carta, V.; Cellamare, S.; Carotti, A.; Genchi, G.; De Sarro, G. Farmaco 1994, 49, 313-323.
25. (a) Hansch, C.; Leo, A. The FRAGMENT method of calculating partition coefficients. In Substituent constants for correlation analysis in chemistry and biology. Wiley: New York, 1979; pp 18-43.
26. (b) Hansch, C.; Leo, A.; Hoekman, D. Exploring QSAR. Hydrophobic, Electronic, and Steric Constants, ACS Professional Reference Book; American Chemical Society: Washington, DC, 1995.
27. (c) Van de Waterbeemb, H.; Testa, B. The parametrization of lipophilicity and other structural properties in drug design. In Advances in Drug Research; Testa, B., Ed.; Academic Press: London, U.K., 1987; Vol. 16, pp 85-225.
28. MacLog P 2.0 program. BioByte Corp., Claremont, CA.
29. Leo, A. J. The future of log P calculation. In Lipophilicity in Drug Action and Toxicology. Methods and principles in Medicinal Chemistry; Pliska, V., Testa, B., Van de Waterbeemd, H., Eds.; VCH Verlagsgesellschaft: Weinheim, D, 1996; Vol. 4, pp 157-171.
30. Dorsey, J. G.; Dill, K. A. The molecular mechanism of retention in reversed-phase liquid chromatography. Chem. Rev. 1989, 89, 331-346.
31. (a) Melander, W.; Campbell, D. E.; Horvatth, Cs. Enthalpyentropy compensation in reversed-phase chromatography. J. Chromatogr. 1978, 158, 215-225.
32. (b) Tomlinson, E. Enthalpyentropy compensation analysis of pharmaceutical biochemical and biological systems. Int. J. Pharm. 1983, 13, 115-144.
33. (c) Lumry, R.; Rajender, S. Enthalpy-entropy compensation phenomena in water solutions of proteins and small molecules: a ubiquitous property of water. Biopolymers 1970, 9, 1125-1227.
34. (d) Tomlinson, E.; Poppe, H.; Kraak, J. C. Thermodynamics of functional groups in reversed-phase high performance liquid-solid chromatography. Int. J. Pharm. 1981, 7, 225-243.
35. (e) Repond, C.; Mayer, J. M.; Van de Waterbeemd, H.; Testa, B.; Linert, W. Thermodynamics and mechanism of partitioning of pyridylalkanamides in n-octanol/water and di-n-butyl ether/ water. Int. J. Pharm. 1987, 38, 47-57.
36. Weissbach, H.; Smith, T. E.; Daly, J. W.; Witkop, B.; Udenfriend, S. A rapid spectrophotometric assay of monoamine oxidase based on the rate of disappearance of kynuramine. J. Biol. Chem. 1960, 235, 1160-1163.
37. Thull, U.; Testa, B. Screening of unsubstituted cyclic compounds as inhibitors of monoamine oxidases. Biochem. Pharmacol. 1994, 47, 2307-2310.
38. (a) Da Y.-Z.; Ito, K.; Fujiwara, H. Energy aspects of oil/water partition leading to the novel hydrophobic parameters for the analysis of quantitative structure-activity relationships. J. Med. Chem. 1992, 35, 3382-3387.
39. (b) Da, Y.-Z., Yanagi, J.; Tanaka, K.; Fujiwara, H. Termochemical aspects of partition. Quantitative structure-activity relationships of benzyldimethylalkylammonium chlorides. Chem. Pharm. Bull. 1993, 41 227-230.
40. (c) Kai, J.; Nakamura, K.; Masuda, T.; Ueda, I.; Fujiwara, H. Thermodynamic aspects of hydrophobicity and the blood-brain barrier permeability studied with a gel filtration chromatography. J. Med. Chem. 1996, 39, 2621-2624.
41. (a) Mazouz, F.; Lebreton, L.; Milcent, R.; Burstein, C. Inhibition of monoamine oxidase types A and B by 2-aryl-4H-1,3,4-oxadiazin-5(6H)-one derivatives. Eur. J Med. Chem. 1988, 23, 441-451.
42. (b) Mazouz, F.; Lebreton, L.; Milcent, R.; Burstein, C. 5-Aryl-1,3,4-oxadiazol-2(3H)-one derivatives and sulfur analogues as new selective and competitive monoamine oxidase type B inhibitors. Eur. J. Med. Chem. 1990, 25, 659-671.
43. (c) Castelli, F.; Pignatello. R.; Sarpietro, M. G.; Mazzone, P.; Raciti, G.; Mazzone, G. Correlation between monoamino oxidase inhibitor activity of some thiazol-2-ylhydrazines and their interaction with dipalmitoylphopsphatidilcoline liposomes. J. Pharm. Sci. 1994, 83, 362-366.
44. Wouters, J.; Ooms, F.; Jegham, S.; Koenig, J. J.; George, P.; Durant, F. Reversible inhibition of type B monoamine oxidase. Theoretical study of model diazo heterocyclic compounds. Eur. J. Med. Chem. 1997, 32, 721-730.
45. (a) Moureau, F.; Wouters, J.; Vercauteren, D. P.; Collin, S.; Evrad, G.; Durant, F.; Ducrey, F.; Koenig, J. J.; Jarreau, F. X. A reversible monoamine oxidase inhibitor, Toloxatone: Spectrophotometric and molecular orbital studies of the interaction with flavin adenine dinucleotide (FAD). Eur. J. Med. Chem. 1994, 29, 269-277.
46. (b) Moureau, F.; Wouters, J.; Depas, M.; Vercauteren, D. P.; Durant, F.; Ducrey, F.; Koenig, J. J.; Jarreau, F. X. A reversible monoamine oxidase inhibitor, Toloxatone: Comparison of its physicochemical properties with those of other inhibitors including Brofaromine, Harmine, R40519 and Moclobemide. Eur. J. Med. Chem. 1995, 30, 823-838.
47. Stetter, H.; Halse, W. Addition of aldehydes to cyclic α-methylene ketones. Chem. Ber. 1984, 117, 682-693.
48. Wagner, R. M.; Jutz, C. A variance of the pyrimidine synthesis. Chem. Ber. 1971, 104, 2975-2983.
49. Krug, R. R.; Hunter, W. G., Grieger, R. A. Enthalpy-entropy compensation. 2. Separation of the chemical from the statistical effects. J. Phys. Chem. 1976, 80, 2341-2351.
50. Sheldrick, G. M. SHELXS-86 Program for Crystal Structure Determination. Acta Crystallogr. 1990, A46, 467-473.
51. Sheldrick, G. M. SHELXL-93, Universität Göttingen, Göttingen, Germany.
52. Hall, S. R.; du Boulay, D. Xtal_GX, Editors. University of Western Australia, Australia.
53. Clark, J. B.; Nicklas, W. J. The metabolism of rat brain mitochondria. J. Biol. Chem. 1970, 245, 4724-4731.
54. Walther, B.; Ghersi-Egea, J.; Minn, A.; Siest, G. Brain mitochondrial cytochrome P-450scc: Spectral and catalytic properties. Arch. Biochem. Biophys. 1987, 254, 592-596.
55. Thull, U.; Kneubühler, S.; Testa, B.; Borges, M. F. M.; Pinto, M. M. M. Substituted xanthones as selective and reversible monoamine oxidase A (MAO-A) inhibitors. Pharm. Res. 1993, 10, 1187-1190.
56. Lowry, O.; Rosebrough, N.; Lewis Farr, A.; Randall, R. Protein measurement with the folin phenol reagent. J. Biol. Chem. 1951, 193, 265-275.
57. Forina, M.; Leardi, R.; Armanino, C.; Lanteri, S.; Conti, P.; Princi, P. Parvus: an Extendable Package of Programs for Data Exploration, Classification and Correlation; Elsevier Scientific Software: Amsterdam, 1988.